Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients
Aims. The aim of this study was to evaluate the potential of visualizing chronic myocardial infarction in patients using the intravascular CA MS-325 (gadofosveset, EPIX Pharmaceuticals, Mass, USA). Methods. Nine patients were enrolled in a clinical phase II multicenter trial for MRCA and perfusion i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/236401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564001831124992 |
|---|---|
| author | Thomas Thouet Bernhard Schnackenburg Thomas Kokocinski Eckart Fleck Eike Nagel Sebastian Kelle |
| author_facet | Thomas Thouet Bernhard Schnackenburg Thomas Kokocinski Eckart Fleck Eike Nagel Sebastian Kelle |
| author_sort | Thomas Thouet |
| collection | DOAJ |
| description | Aims. The aim of this study was to evaluate the potential of visualizing chronic myocardial infarction in patients using the intravascular CA MS-325 (gadofosveset, EPIX Pharmaceuticals, Mass, USA). Methods. Nine patients were enrolled in a clinical phase II multicenter trial for MRCA and perfusion imaging using MS-325. They had objective evidence of chronic myocardial infarction as visualized by previously performed late gadolinium (Gd) enhancement imaging (LGE) with a conventional extracellular Gd-DTPA CA (Magnevist, Bayer Healthcare, Germany, 0.2 mmol/kg/body weight) serving as reference standard. A prepulse-optimized LGE study was performed immediately and at several time points after injection of MS-325 (0.05 mmol/kg/body weight). The number and localization of segments demonstrating LGE with MS-325 as well as signal intensities were compared with the reference standard (Gd-DTPA). Results. Using MS-325, LGE could be detected at every time point in all 9 patients. The accuracy of LGE with MS-325 as compared to LGE with Gd-DTPA was highest 54±4 minutes after contrast injection, resulting in a sensitivity of 84% with a specificity of 98%. Conclusion. The intravascular CA MS-325 has the potential to visualize chronic myocardial infarction. However, in comparison with Gd-DTPA, the transmural extent and the number of segments are smaller. |
| format | Article |
| id | doaj-art-998711bcef774fb1b52ae0688b13cfb4 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-998711bcef774fb1b52ae0688b13cfb42025-02-03T01:12:07ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/236401236401Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in PatientsThomas Thouet0Bernhard Schnackenburg1Thomas Kokocinski2Eckart Fleck3Eike Nagel4Sebastian Kelle5Department of Internal Medicine/Cardiology, German Heart Institute Berlin, 13353 Berlin, GermanyPhilips Healthcare, 20099 Hamburg, GermanyDepartment of Internal Medicine/Cardiology, German Heart Institute Berlin, 13353 Berlin, GermanyDepartment of Internal Medicine/Cardiology, German Heart Institute Berlin, 13353 Berlin, GermanyDivision of Imaging Sciences and Medical Engineering, Department of Cardiovascular Imaging, King's College London, London 5E1 7EH, UKDepartment of Internal Medicine/Cardiology, German Heart Institute Berlin, 13353 Berlin, GermanyAims. The aim of this study was to evaluate the potential of visualizing chronic myocardial infarction in patients using the intravascular CA MS-325 (gadofosveset, EPIX Pharmaceuticals, Mass, USA). Methods. Nine patients were enrolled in a clinical phase II multicenter trial for MRCA and perfusion imaging using MS-325. They had objective evidence of chronic myocardial infarction as visualized by previously performed late gadolinium (Gd) enhancement imaging (LGE) with a conventional extracellular Gd-DTPA CA (Magnevist, Bayer Healthcare, Germany, 0.2 mmol/kg/body weight) serving as reference standard. A prepulse-optimized LGE study was performed immediately and at several time points after injection of MS-325 (0.05 mmol/kg/body weight). The number and localization of segments demonstrating LGE with MS-325 as well as signal intensities were compared with the reference standard (Gd-DTPA). Results. Using MS-325, LGE could be detected at every time point in all 9 patients. The accuracy of LGE with MS-325 as compared to LGE with Gd-DTPA was highest 54±4 minutes after contrast injection, resulting in a sensitivity of 84% with a specificity of 98%. Conclusion. The intravascular CA MS-325 has the potential to visualize chronic myocardial infarction. However, in comparison with Gd-DTPA, the transmural extent and the number of segments are smaller.http://dx.doi.org/10.1100/2012/236401 |
| spellingShingle | Thomas Thouet Bernhard Schnackenburg Thomas Kokocinski Eckart Fleck Eike Nagel Sebastian Kelle Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients The Scientific World Journal |
| title | Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients |
| title_full | Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients |
| title_fullStr | Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients |
| title_full_unstemmed | Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients |
| title_short | Visualization of Chronic Myocardial Infarction Using the Intravascular Contrast Agent MS-325 (Gadofosveset) in Patients |
| title_sort | visualization of chronic myocardial infarction using the intravascular contrast agent ms 325 gadofosveset in patients |
| url | http://dx.doi.org/10.1100/2012/236401 |
| work_keys_str_mv | AT thomasthouet visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients AT bernhardschnackenburg visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients AT thomaskokocinski visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients AT eckartfleck visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients AT eikenagel visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients AT sebastiankelle visualizationofchronicmyocardialinfarctionusingtheintravascularcontrastagentms325gadofosvesetinpatients |